With increasing success of cancer therapy in childhood detection, treatment and possibly avoidance of long term sequelae after anti-neoplastic therapy and the aftercare of these patients are of great importance today. The "Late Effects Surveillance System (LESS)" of the GPOH, established in 1995, collects systematically data on major late effects of patients treated according to the therapy optimising studies to answer the questions about incidence and latency after first line treatment as well as prognosis. The most significant late effects known today are cardio-toxicity mainly after therapy with anthracyclines, oto- and nephrotoxicity after platinum derivatives, tubulopathy after ifosfamide and endocrine dysfunctions causing deficiencies in growth, pubertal development and fertility. Furthermore the risk of secondary neoplasia is an important issue in the management of these patients. This is investigated by the German Childhood Cancer Registry. Knowledge of a structured aftercare in the frame work of a vertical network provides the basis of efficient care and counselling of cancer survivors in childhood and adolescence.
|Translated title of the contribution||Survivors of childhood cancer: Aftercare and late effects after successful treatment|
|Journal||Monatsschrift fur Kinderheilkunde|
|Number of pages||12|
|Publication status||Published - 2002|
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)